Clinical trial news

SMA research grant

AVXS-101 may become a valuable gene therapy option for babies with spinal muscular atrophy (SMA) type 1, according to the results of a Phase 1 clinical trial conducted by AveXis. SMA is caused by mutations in the SMN gene, which leads to the impairment of motor neurons, which work to…

Cytokinetics has begun enrolling a second group of patients for a Phase 2 clinical trial of CK-2127107 as a treatment for spinal muscular atrophy (SMA). The announcement follows an independent Data Monitoring Committee’s review of the therapy’s safety, absorption, distribution, metabolism, and excretion in Cohort 1. The randomized, double-blind, placebo-controlled,…

This video from Nemours Children’s Hospital shows the effects of the drug nusinersen (Spinraza) on a young spinal muscular atrophy (SMA) patient. Find out more about nusinersen (Spinraza) in the webinar.  Three-year-old Asher Camp from Florida was diagnosed with type 1 SMA when he was six months old,…

Vivonoetics equipment in Roche trial

Vivonoetics is partnering with Great Lakes NeuroTechnologies to provide advanced respiratory assessment to the Roche FIREFISH Phase 2 clinical trial in infants with type 1 spinal muscular atrophy type 1 (SMA-1). Vivonoetics is the developer of VivoSense data analysis and software and wearable monitoring devices that have supported research…